posted
BOHEMIA, N.Y., Dec 17, 2007 (BUSINESS WIRE) -- Advanced BioPhotonics Inc announced today that it has completed its initial phase and review of the clinical trial protocol previously announced earlier this year. This trial is investigating the use of Advanced BioPhotonics' patented BioScanIR(R) System, together with its proprietary DIRI(R) method of dynamic infrared imaging in detecting and assessing pigmented lesions of the skin including melanoma and other forms of skin cancer. In a review of the first twenty-four cases, the BioScanIR(R) was able to correctly identify all four melanomas including a melanoma in situ as well as accurately identifying 80% of the benign lesions as confirmed by biopsy and/or clinical examination. Although this phase is a small sample size, the principal investigator at the institution called the findings encouraging and promising. The next phase of the study will focus on lesion characterization to help further improve the system's performance. It is expected that the next phase will take several months to complete.
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
posted
More news to come - this is only the begining.
***** Posted by: Aufan 1983 In reply to: Stocks4Blondie who wrote msg# 150 Date:12/18/2007 12:09:32 PM Post #of 151
Welcome aboard Blondie...
Good things to come (IMO) We are still awaiting the biggest news.
Keep in mind mm's will play games but our day will come and I think it will be pretty soon
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
posted
y is every trade two trades for the same amount just a .001 difference and occur at the same exact time. I have seen this before. Its mirror trading, right? What is the point of this. Sorry I am learning, but still have alot left to learn with these pennnies, so I prolly ask some dumb questions sometimes
-------------------- I hope this goes Posts: 111 | From: trenton nj | Registered: Sep 2006
| IP: Logged |
0.009 X 0.010 **** Very strong bid support for a great run, more shakes are along the way though. ****** MM ID Bid Size Time UBSS 0.0084 5000 12:36:37 ARCA 0.0084 5000 12:36:11 EDGX 0.0083 5000 12:36:02 NITE 0.0080 10000 12:30:42 SBSH 0.0080 5000 12:36:31 HILL 0.0080 5000 12:30:57 HDSN 0.0080 5000 12:30:50 DOMS 0.0065 5000 10:33:19 MAXM 0.0025 5000 10:27:04 SALI 0.0020 5000 07:30:00 VERT 0.0010 5000 07:30:00 VFIN 0.0001 5000 07:30:00 ETRD 0.0001 5000 10:46
**** Posted by: Aufan 1983 In reply to: None Date:12/18/2007 11:57:16 AM Post #of 159
From 10QSB.... For those undecided read the bold
Plan of Operations
Planned Clinical Trials in 2007.
· Pigmented Lesions of the Skin assessment (Melanoma). Melanoma detection and assessment represents a large clinical problem and a disease state where the BioScanIR® system may readily measure and assess the primary photonic emissions of skin tumors. In July 2007, we began a pilot research trial at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School. The first results for this trial are anticipated to be available in the third quarter 2007.
· Adjunctive screening and detection of breast cancer. The use of the BioScanIR® system as an adjunctive technique in breast cancer detection in certain age categories still holds great promise. This application may be particularly useful in younger women (under 50 years of age) with dense breasts who are at increased risk for breast cancer. We will continue to support the current work being done at the State University of New York Stony Brook in this area. First results should be available in late 2007.
We intend to concentrate our efforts and pursue clinical trials in the above noted applications provided that we have sufficient funds to do so. Previously, we had reported that we had also intended to organize a clinical trial to test the assessment of peripheral perfusion. The assessment of peripheral perfusion after tourniquet stress is a non invasive method of measuring peripheral outflow as a measure of systemic vascular disease. The current methods employ ultrasound techniques over which we may have significant benefits. After further investigation, we have decided to focus our limited assets on pigmented lesions of the skin assessment (Melanoma) and adjunctive screening and detection of breast cancer. As of August 1, 2007, we had two fully functional prototype or commercial units installed in various U.S. medical institutions for testing and evaluation.
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
posted
Nite just raised bid to 0.008 - he intended to push it up for an extended run. Watch it.
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
More news to come: **** Posted by: mgland In reply to: cashwealth who wrote msg# 180 Date:12/18/2007 4:04:35 PM Post #of 184
Reminder. ABPH.Stay tuned for the Breast cancer mapping of younger women results. Culmination of three years study. Due before end of year. A method of non invasive tracking and mapping for this group. A JV or they will be aquired. JMHO
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
